Portal vein embolization stimulates tumour growth in patients with colorectal cancer liver metastases
Portal vein embolization (PVE) can facilitate the resection of previously unresectable colorectal cancer (CRC) liver metastases. Bevacizumab is being used increasingly in the treatment of metastatic CRC, although data regarding its effect on post-embolization liver regeneration and tumour growth are...
Saved in:
| Published in | HPB (Oxford, England) Vol. 14; no. 7; pp. 461 - 468 |
|---|---|
| Main Authors | , , , , , , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
Oxford, UK
Elsevier Ltd
01.07.2012
Blackwell Publishing Ltd |
| Subjects | |
| Online Access | Get full text |
| ISSN | 1365-182X 1477-2574 1477-2574 |
| DOI | 10.1111/j.1477-2574.2012.00476.x |
Cover
Loading…
| Abstract | Portal vein embolization (PVE) can facilitate the resection of previously unresectable colorectal cancer (CRC) liver metastases. Bevacizumab is being used increasingly in the treatment of metastatic CRC, although data regarding its effect on post-embolization liver regeneration and tumour growth are conflicting. The objective of this observational study was to assess the impact of pre-embolization bevacizumab on liver hypertrophy and tumour growth.
Computed tomography scans before and 4weeks after PVE were evaluated in patients who received perioperative chemotherapy with or without bevacizumab. Scans were compared with scans obtained in a control group in which no PVE was administered. Future liver remnant (FLR), total liver volume (TLV) and total tumour volume (TTV) were measured. Bevacizumab was discontinued ≥4weeks before PVE.
A total of 109 patients and 11 control patients were included. Portal vein embolization induced a significant increase in TTV: the right lobe increased by 33.4% in PVE subjects but decreased by 34.8% in control subjects (P < 0.001), and the left lobe increased by 49.9% in PVE subjects and decreased by 33.2% in controls (P= 0.022). A total of 52.8% of the study group received bevacizumab and 47.2% did not. There was no statistical difference between the two chemotherapy groups in terms of tumour growth. Median FLR after PVE was similar in both groups (28.8% vs. 28.7%; P= 0.825).
Adequate liver regeneration was achieved in patients who underwent PVE. However, significant tumour progression was also observed post-embolization. |
|---|---|
| AbstractList | Objectives: Portal vein embolization (PVE) can facilitate the resection of previously unresectable colorectal cancer (CRC) liver metastases. Bevacizumab is being used increasingly in the treatment of metastatic CRC, although data regarding its effect on post‐embolization liver regeneration and tumour growth are conflicting. The objective of this observational study was to assess the impact of pre‐embolization bevacizumab on liver hypertrophy and tumour growth.
Methods: Computed tomography scans before and 4 weeks after PVE were evaluated in patients who received perioperative chemotherapy with or without bevacizumab. Scans were compared with scans obtained in a control group in which no PVE was administered. Future liver remnant (FLR), total liver volume (TLV) and total tumour volume (TTV) were measured. Bevacizumab was discontinued ≥ 4 weeks before PVE.
Results: A total of 109 patients and 11 control patients were included. Portal vein embolization induced a significant increase in TTV: the right lobe increased by 33.4% in PVE subjects but decreased by 34.8% in control subjects (P < 0.001), and the left lobe increased by 49.9% in PVE subjects and decreased by 33.2% in controls (P= 0.022). A total of 52.8% of the study group received bevacizumab and 47.2% did not. There was no statistical difference between the two chemotherapy groups in terms of tumour growth. Median FLR after PVE was similar in both groups (28.8% vs. 28.7%; P= 0.825).
Conclusions: Adequate liver regeneration was achieved in patients who underwent PVE. However, significant tumour progression was also observed post‐embolization. Abstract Objectives Portal vein embolization (PVE) can facilitate the resection of previously unresectable colorectal cancer (CRC) liver metastases. Bevacizumab is being used increasingly in the treatment of metastatic CRC, although data regarding its effect on post-embolization liver regeneration and tumour growth are conflicting. The objective of this observational study was to assess the impact of pre-embolization bevacizumab on liver hypertrophy and tumour growth. Methods Computed tomography scans before and 4 weeks after PVE were evaluated in patients who received perioperative chemotherapy with or without bevacizumab. Scans were compared with scans obtained in a control group in which no PVE was administered. Future liver remnant (FLR), total liver volume (TLV) and total tumour volume (TTV) were measured. Bevacizumab was discontinued ≥ 4 weeks before PVE. Results A total of 109 patients and 11 control patients were included. Portal vein embolization induced a significant increase in TTV: the right lobe increased by 33.4% in PVE subjects but decreased by 34.8% in control subjects ( P < 0.001), and the left lobe increased by 49.9% in PVE subjects and decreased by 33.2% in controls ( P = 0.022). A total of 52.8% of the study group received bevacizumab and 47.2% did not. There was no statistical difference between the two chemotherapy groups in terms of tumour growth. Median FLR after PVE was similar in both groups (28.8% vs. 28.7%; P = 0.825). Conclusions Adequate liver regeneration was achieved in patients who underwent PVE. However, significant tumour progression was also observed post-embolization. Portal vein embolization (PVE) can facilitate the resection of previously unresectable colorectal cancer (CRC) liver metastases. Bevacizumab is being used increasingly in the treatment of metastatic CRC, although data regarding its effect on post-embolization liver regeneration and tumour growth are conflicting. The objective of this observational study was to assess the impact of pre-embolization bevacizumab on liver hypertrophy and tumour growth.OBJECTIVESPortal vein embolization (PVE) can facilitate the resection of previously unresectable colorectal cancer (CRC) liver metastases. Bevacizumab is being used increasingly in the treatment of metastatic CRC, although data regarding its effect on post-embolization liver regeneration and tumour growth are conflicting. The objective of this observational study was to assess the impact of pre-embolization bevacizumab on liver hypertrophy and tumour growth.Computed tomography scans before and 4 weeks after PVE were evaluated in patients who received perioperative chemotherapy with or without bevacizumab. Scans were compared with scans obtained in a control group in which no PVE was administered. Future liver remnant (FLR), total liver volume (TLV) and total tumour volume (TTV) were measured. Bevacizumab was discontinued ≥ 4 weeks before PVE.METHODSComputed tomography scans before and 4 weeks after PVE were evaluated in patients who received perioperative chemotherapy with or without bevacizumab. Scans were compared with scans obtained in a control group in which no PVE was administered. Future liver remnant (FLR), total liver volume (TLV) and total tumour volume (TTV) were measured. Bevacizumab was discontinued ≥ 4 weeks before PVE.A total of 109 patients and 11 control patients were included. Portal vein embolization induced a significant increase in TTV: the right lobe increased by 33.4% in PVE subjects but decreased by 34.8% in control subjects (P < 0.001), and the left lobe increased by 49.9% in PVE subjects and decreased by 33.2% in controls (P= 0.022). A total of 52.8% of the study group received bevacizumab and 47.2% did not. There was no statistical difference between the two chemotherapy groups in terms of tumour growth. Median FLR after PVE was similar in both groups (28.8% vs. 28.7%; P= 0.825).RESULTSA total of 109 patients and 11 control patients were included. Portal vein embolization induced a significant increase in TTV: the right lobe increased by 33.4% in PVE subjects but decreased by 34.8% in control subjects (P < 0.001), and the left lobe increased by 49.9% in PVE subjects and decreased by 33.2% in controls (P= 0.022). A total of 52.8% of the study group received bevacizumab and 47.2% did not. There was no statistical difference between the two chemotherapy groups in terms of tumour growth. Median FLR after PVE was similar in both groups (28.8% vs. 28.7%; P= 0.825).Adequate liver regeneration was achieved in patients who underwent PVE. However, significant tumour progression was also observed post-embolization.CONCLUSIONSAdequate liver regeneration was achieved in patients who underwent PVE. However, significant tumour progression was also observed post-embolization. Portal vein embolization (PVE) can facilitate the resection of previously unresectable colorectal cancer (CRC) liver metastases. Bevacizumab is being used increasingly in the treatment of metastatic CRC, although data regarding its effect on post-embolization liver regeneration and tumour growth are conflicting. The objective of this observational study was to assess the impact of pre-embolization bevacizumab on liver hypertrophy and tumour growth. Computed tomography scans before and 4 weeks after PVE were evaluated in patients who received perioperative chemotherapy with or without bevacizumab. Scans were compared with scans obtained in a control group in which no PVE was administered. Future liver remnant (FLR), total liver volume (TLV) and total tumour volume (TTV) were measured. Bevacizumab was discontinued ≥ 4 weeks before PVE. A total of 109 patients and 11 control patients were included. Portal vein embolization induced a significant increase in TTV: the right lobe increased by 33.4% in PVE subjects but decreased by 34.8% in control subjects (P < 0.001), and the left lobe increased by 49.9% in PVE subjects and decreased by 33.2% in controls (P= 0.022). A total of 52.8% of the study group received bevacizumab and 47.2% did not. There was no statistical difference between the two chemotherapy groups in terms of tumour growth. Median FLR after PVE was similar in both groups (28.8% vs. 28.7%; P= 0.825). Adequate liver regeneration was achieved in patients who underwent PVE. However, significant tumour progression was also observed post-embolization. Portal vein embolization (PVE) can facilitate the resection of previously unresectable colorectal cancer (CRC) liver metastases. Bevacizumab is being used increasingly in the treatment of metastatic CRC, although data regarding its effect on post-embolization liver regeneration and tumour growth are conflicting. The objective of this observational study was to assess the impact of pre-embolization bevacizumab on liver hypertrophy and tumour growth. Computed tomography scans before and 4weeks after PVE were evaluated in patients who received perioperative chemotherapy with or without bevacizumab. Scans were compared with scans obtained in a control group in which no PVE was administered. Future liver remnant (FLR), total liver volume (TLV) and total tumour volume (TTV) were measured. Bevacizumab was discontinued ≥4weeks before PVE. A total of 109 patients and 11 control patients were included. Portal vein embolization induced a significant increase in TTV: the right lobe increased by 33.4% in PVE subjects but decreased by 34.8% in control subjects (P < 0.001), and the left lobe increased by 49.9% in PVE subjects and decreased by 33.2% in controls (P= 0.022). A total of 52.8% of the study group received bevacizumab and 47.2% did not. There was no statistical difference between the two chemotherapy groups in terms of tumour growth. Median FLR after PVE was similar in both groups (28.8% vs. 28.7%; P= 0.825). Adequate liver regeneration was achieved in patients who underwent PVE. However, significant tumour progression was also observed post-embolization. |
| Author | Hassanain, Mazen Abualhassan, Nasser Aljiffry, Murad Chaudhury, Prosanto Kavan, Petr Salman, Ayat Al-Abbad, Saleh Simoneau, Eve El Baage, Arwa Cabrera, Tatiana Valenti, David Jamal, Mohammad Metrakos, Peter |
| Author_xml | – sequence: 1 givenname: Eve surname: Simoneau fullname: Simoneau, Eve organization: Section of Solid Organ Transplant and Hepatopancreatobiliary Surgery – sequence: 2 givenname: Murad surname: Aljiffry fullname: Aljiffry, Murad organization: Section of Solid Organ Transplant and Hepatopancreatobiliary Surgery – sequence: 3 givenname: Ayat surname: Salman fullname: Salman, Ayat organization: Section of Solid Organ Transplant and Hepatopancreatobiliary Surgery – sequence: 4 givenname: Nasser surname: Abualhassan fullname: Abualhassan, Nasser organization: Section of Solid Organ Transplant and Hepatopancreatobiliary Surgery – sequence: 5 givenname: Tatiana surname: Cabrera fullname: Cabrera, Tatiana organization: Departments of Radiology – sequence: 6 givenname: David surname: Valenti fullname: Valenti, David organization: Departments of Radiology – sequence: 7 givenname: Arwa surname: El Baage fullname: El Baage, Arwa organization: Department of Surgery, College of Medicine, King Saud University, Riyadh, Saudi Arabia – sequence: 8 givenname: Mohammad surname: Jamal fullname: Jamal, Mohammad organization: Section of Solid Organ Transplant and Hepatopancreatobiliary Surgery – sequence: 9 givenname: Petr surname: Kavan fullname: Kavan, Petr organization: Oncology, McGill University Health Center, Montreal, QC, Canada – sequence: 10 givenname: Saleh surname: Al-Abbad fullname: Al-Abbad, Saleh organization: Section of Solid Organ Transplant and Hepatopancreatobiliary Surgery – sequence: 11 givenname: Prosanto surname: Chaudhury fullname: Chaudhury, Prosanto organization: Section of Solid Organ Transplant and Hepatopancreatobiliary Surgery – sequence: 12 givenname: Mazen surname: Hassanain fullname: Hassanain, Mazen email: mazen.hassanain@mail.mcgill.ca organization: Section of Solid Organ Transplant and Hepatopancreatobiliary Surgery – sequence: 13 givenname: Peter surname: Metrakos fullname: Metrakos, Peter organization: Section of Solid Organ Transplant and Hepatopancreatobiliary Surgery |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/22672548$$D View this record in MEDLINE/PubMed |
| BookMark | eNqVUl1v0zAUjdAQ-4C_gPLIS0rsJHYiIQSbYEOrxiSGytuV69xs7py42E7b8etx2hHgAalYlm3Z5557fc85jg4602EUxSSdkDBeLyYk5zyhBc8nNCV0kqY5Z5PNk-hofDgI54wVCSnpt8Po2LlFmlKSkupZdEgp47TIy6MIr431QscrVF2M7dxo9UN4ZbrYedX2Wnh0se9b09v41pq1v4sDcBkg2HkXr1W4kEYbi3KgkaKTaGOtVmFt0QsXJrrn0dNGaIcvHveT6OvHDzdnF8n08_mns_fTRLKSsiSf17KWjSCCESk5oqBFw2hT8kryBkVBKo6yqStWNlktmGBVnqVZ0fCKUJHz7CR6u-Nd9vMWaxlqtELD0qpW2AcwQsHfL526g1uzgiwr85KzQPDqkcCa7z06D61yErUWHZrewdA_RrKcDNCXf-Yak_zqbQCUO4C0xjmLzQghKQwywgIGtWBQCwYZYSsjbH7_YwyVym9lCVUrvQ_Bmx3BWml82DsxXFyf5ts2JLtw5TxuxnBh74HxjBcwuzqHq9nshswup3AZ8Kc7PAZxVwotOBkMIrFWgzGgNuo_Pj2SSK06JYW-xwd0i2DBLpgHCLgQBF8Gdw_mJkWWDpoEgnf_Jtivhp8hYwh8 |
| CitedBy_id | crossref_primary_10_1186_s12957_017_1212_6 crossref_primary_10_1007_s11605_022_05551_2 crossref_primary_10_3748_wjg_v21_i15_4491 crossref_primary_10_1002_cncr_30390 crossref_primary_10_1007_s10330_015_0083_y crossref_primary_10_1007_s40336_016_0172_0 crossref_primary_10_1245_s10434_023_13750_7 crossref_primary_10_1016_j_hpb_2017_03_003 crossref_primary_10_1016_j_suronc_2020_07_001 crossref_primary_10_1016_j_hpb_2017_08_030 crossref_primary_10_3892_or_2017_5531 crossref_primary_10_1080_00015458_2022_2056680 crossref_primary_10_1016_j_jhepr_2022_100484 crossref_primary_10_12659_MSM_899941 crossref_primary_10_1016_j_hpb_2023_06_005 crossref_primary_10_1016_j_jvir_2014_01_034 crossref_primary_10_3390_jcm10092003 crossref_primary_10_1007_s00330_019_06101_2 crossref_primary_10_3109_13645706_2014_897955 crossref_primary_10_1016_j_jss_2012_10_032 crossref_primary_10_1371_journal_pone_0307937 crossref_primary_10_1016_j_ijsu_2018_11_029 crossref_primary_10_1002_jhbp_77 crossref_primary_10_18528_gii180010 crossref_primary_10_1007_s11912_020_00922_x crossref_primary_10_1016_j_heliyon_2024_e27578 crossref_primary_10_1007_s11888_013_0159_4 crossref_primary_10_1016_j_hpb_2019_06_014 crossref_primary_10_1007_s00740_014_0218_8 crossref_primary_10_1093_bjr_tqaf003 crossref_primary_10_1007_s00270_020_02416_6 crossref_primary_10_1245_s10434_021_10525_w crossref_primary_10_1016_j_hpb_2018_07_002 crossref_primary_10_1111_hpb_12397 crossref_primary_10_1148_radiol_2015141858 crossref_primary_10_1159_000517025 crossref_primary_10_1186_s12885_023_11280_9 crossref_primary_10_1097_SLA_0000000000001046 crossref_primary_10_2217_crc_2016_0004 crossref_primary_10_1007_s10585_017_9855_9 crossref_primary_10_3390_cancers12061638 crossref_primary_10_1016_j_jvir_2012_10_017 crossref_primary_10_1016_j_surg_2013_02_001 crossref_primary_10_1007_s11912_014_0407_z crossref_primary_10_1016_j_ijscr_2014_11_008 crossref_primary_10_1016_j_surg_2014_12_009 crossref_primary_10_1016_j_hpb_2020_02_008 crossref_primary_10_1007_s10353_015_0381_1 crossref_primary_10_1002_jso_24139 crossref_primary_10_1111_j_1477_2574_2012_00543_x crossref_primary_10_1186_s12893_020_00721_y crossref_primary_10_1002_hep_26947 crossref_primary_10_3389_fonc_2023_963966 crossref_primary_10_3390_cancers13020200 crossref_primary_10_1007_s13304_024_01789_4 |
| Cites_doi | 10.1016/j.jamcollsurg.2005.11.008 10.1200/JCO.2008.17.7147 10.1245/s10434-009-0447-z 10.1016/j.surg.2010.10.012 10.1245/s10434-008-0035-7 10.1002/cncr.23099 10.1186/1756-9966-29-58 10.3322/caac.20138 10.3322/caac.20073 10.1097/PAS.0b013e3181eb2f7b 10.1007/s11605-009-1073-6 10.1016/j.jhep.2006.02.020 10.1592/phco.28.11-supp.18S 10.1056/NEJMoa032691 10.1002/bjs.6756 10.1111/j.1477-2574.2009.00119.x 10.1002/bjs.5836 10.1001/archsurg.137.6.675 10.1093/annonc/mdp533 10.1093/annonc/mdl386 10.1159/000184735 10.1053/jhep.2001.26513 10.1046/j.1365-2168.1999.01154.x 10.1200/JCO.2008.20.5278 10.1097/01.SLA.0000065265.16728.C0 10.1200/JCO.2007.13.7679 10.1097/SLA.0b013e31815f6e5b 10.1016/j.ejso.2009.12.001 10.1245/s10434-009-0450-4 10.1200/JCO.2007.15.4138 10.1111/j.1477-2574.2009.00004.x 10.1097/SLA.0b013e31815ed693 |
| ContentType | Journal Article |
| Copyright | 2012 International Hepato-Pancreato-Biliary Association International Hepato-Pancreato-Biliary Association 2012 International Hepato‐Pancreato‐Biliary Association 2012 International Hepato-Pancreato-Biliary Association. 2012 International Hepato-Pancreato-Biliary Association 2012 |
| Copyright_xml | – notice: 2012 International Hepato-Pancreato-Biliary Association – notice: International Hepato-Pancreato-Biliary Association – notice: 2012 International Hepato‐Pancreato‐Biliary Association – notice: 2012 International Hepato-Pancreato-Biliary Association. – notice: 2012 International Hepato-Pancreato-Biliary Association 2012 |
| DBID | 6I. AAFTH BSCLL AAYXX CITATION CGR CUY CVF ECM EIF NPM 7X8 5PM |
| DOI | 10.1111/j.1477-2574.2012.00476.x |
| DatabaseName | ScienceDirect Open Access Titles Elsevier:ScienceDirect:Open Access Istex CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic PubMed Central (Full Participant titles) |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic MEDLINE |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1477-2574 |
| EndPage | 468 |
| ExternalDocumentID | PMC3384876 22672548 10_1111_j_1477_2574_2012_00476_x HPB476 ark_67375_WNG_NWWT1WKL_K S1365182X15306134 1_s2_0_S1365182X15306134 |
| Genre | article Research Support, Non-U.S. Gov't Journal Article |
| GroupedDBID | --- .1- .3N .FO .GA .Y3 05W 1OC 1P~ 29I 2WC 31~ 4.4 457 50Y 50Z 52M 52O 52T 52W 53G 5VS 702 7PT 8-0 8-1 8-3 8-4 8-5 930 A01 A03 AAEDW AAEVG AALRI AAMMB AANHP AAONW AAXUO AAYWO ABJNI ABMAC ABPVW ACBWZ ACGEJ ACGFS ACRPL ACVFH ACXQS ACYXJ ADBBV ADCNI ADIZJ ADNMO ADVLN ADXPE AEFGJ AEIMD AENEX AEUPX AEVXI AFBPY AFJKZ AFKVX AFPUW AFRHN AFTJW AGCQF AGHFR AGQPQ AGXDD AHMBA AIDQK AIDYY AIGII AITUG AJAOE AJUYK AJWEG AKBMS AKRWK AKYEP ALAGY ALMA_UNASSIGNED_HOLDINGS AMBMR AMRAJ AOIJS APXCP ASPBG ATUGU AVWKF AZBYB AZFZN BAFTC BAWUL BDRZF BROTX BRXPI CAG COF CS3 D-6 D-7 D-E D-F DCZOG DIK DPXWK E3Z EBS EFKBS EJD F00 F01 F04 F21 F5P FDB FEDTE G-S G.N GODZA GX1 H.X HF~ HOLLA HVGLF HX~ HYE HZ~ LH4 LP6 LP7 LW6 M41 MK4 MY~ N04 N05 NF~ OC. OK1 ON0 OVD P2X P2Z P4B P4D PQQKQ Q.N QB0 R.K ROL RPM RX1 SSZ SUPJJ TEORI TR2 UB1 W8V W99 WYUIH XV2 Z5R ~IA ~WT AACTN AAHHS ACCFJ ADZOD AEEZP AEQDE AFCTW AIWBW AJBDE NCXOZ 6I. AAFTH AAIAV AAVGM ABVKL ACXME WRC BSCLL AAYXX CITATION CGR CUY CVF ECM EIF NPM 7X8 5PM |
| ID | FETCH-LOGICAL-c6826-4bdcdcfa1a61cc7eea25f62f879c7fea5197ecfd968f3da6a6943035f7912a473 |
| ISSN | 1365-182X 1477-2574 |
| IngestDate | Thu Aug 21 13:40:41 EDT 2025 Fri Sep 05 11:14:34 EDT 2025 Wed Feb 19 02:03:01 EST 2025 Tue Jul 01 01:11:50 EDT 2025 Thu Apr 24 23:03:34 EDT 2025 Wed Jan 22 16:20:26 EST 2025 Wed Oct 30 09:54:26 EDT 2024 Fri Feb 23 02:25:23 EST 2024 Sun Feb 23 10:19:17 EST 2025 Tue Aug 26 17:08:18 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 7 |
| Keywords | bevacizumab colorectal cancer liver metastases liver regeneration tumour growth degree of hypertrophy portal vein embolization |
| Language | English |
| License | http://www.elsevier.com/open-access/userlicense/1.0 https://www.elsevier.com/tdm/userlicense/1.0 https://www.elsevier.com/open-access/userlicense/1.0 2012 International Hepato-Pancreato-Biliary Association. |
| LinkModel | OpenURL |
| MergedId | FETCHMERGED-LOGICAL-c6826-4bdcdcfa1a61cc7eea25f62f879c7fea5197ecfd968f3da6a6943035f7912a473 |
| Notes | istex:4837B3CF73075CD420CAAEBB678E07537EBA9069 ArticleID:HPB476 ark:/67375/WNG-NWWT1WKL-K This manuscript was presented at the annual AHPBA 2011 meeting, Miami and at the 2010 IHPBA meeting. These authors contributed equally to this paper as senior authors. ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
| OpenAccessLink | https://dx.doi.org/10.1111/j.1477-2574.2012.00476.x |
| PMID | 22672548 |
| PQID | 1019613416 |
| PQPubID | 23479 |
| PageCount | 8 |
| ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_3384876 proquest_miscellaneous_1019613416 pubmed_primary_22672548 crossref_primary_10_1111_j_1477_2574_2012_00476_x crossref_citationtrail_10_1111_j_1477_2574_2012_00476_x wiley_primary_10_1111_j_1477_2574_2012_00476_x_HPB476 istex_primary_ark_67375_WNG_NWWT1WKL_K elsevier_sciencedirect_doi_10_1111_j_1477_2574_2012_00476_x elsevier_clinicalkeyesjournals_1_s2_0_S1365182X15306134 elsevier_clinicalkey_doi_10_1111_j_1477_2574_2012_00476_x |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | July 2012 |
| PublicationDateYYYYMMDD | 2012-07-01 |
| PublicationDate_xml | – month: 07 year: 2012 text: July 2012 |
| PublicationDecade | 2010 |
| PublicationPlace | Oxford, UK |
| PublicationPlace_xml | – name: Oxford, UK – name: England |
| PublicationTitle | HPB (Oxford, England) |
| PublicationTitleAlternate | HPB (Oxford) |
| PublicationYear | 2012 |
| Publisher | Elsevier Ltd Blackwell Publishing Ltd |
| Publisher_xml | – name: Elsevier Ltd – name: Blackwell Publishing Ltd |
| References | Elias, De Baere, Roche, Ducreux, Leclere, Lasser (bb0105) 1999; 86 Ribero, Abdalla, Madoff, Donadon, Loyer, Vauthey (bb0115) 2007; 94 Ribero, Wang, Donadon, Zorzi, Thomas, Eng (bb0175) 2007; 110 Nafidi, Désy, Létourneau, Côté, Plasse, Vandenbroucke (bb0085) 2009; 11 Rubbia-Brandt, Giostra, Brezault, Roth, Andres, Audard (bb0180) 2007; 18 Engstrom (bb0040) 2008; 28 Donadon, Ribero, Morris-Stiff, Abdalla, Vauthey (bb0170) 2007; 1 (bb0020) 2010 Aussilhou, Dokmak, Faivre, Paradis, Vilgrain, Belghiti (bb0155) 2009; 16 Sanoff, Sargent, Campbell, Morton, Fuchs, Ramanathan (bb0035) 2008; 26 Maggiori, Bretagnol, Sibert, Paradis, Vilgrain, Panis (bb0125) 2010; 149 Gruenberger, Tamandl, Schueller, Scheithauer, Zielinski, Herbst (bb0140) 2008; 26 Chaudhury, Hassanain, Bouganim, Salman, Kavan, Metrakos (bb0145) 2010; 12 Siegel, Naishadham, Jemal (bb0015) 2012; 62 Shah, Haddad, Al-Sukhni, Kim, Greig, Grant (bb0030) 2006; 202 van Gulik, van den Esschert, de Graaf, van Lienden, Busch, Heger (bb0130) 2008; 25 Heinrich, Jochum, Graf, Clavien (bb0120) 2006; 45 Hurwitz, Fehrenbacher, Novotny, Cartwright, Hainsworth, Heim (bb0045) 2004; 350 Hochster, Hart, Ramanathan, Childs, Hainsworth, Cohn (bb0050) 2008; 26 Sturesson, Keussen, Tranberg (bb0160) 2010; 36 Zorzi, Chun, Madoff, Abdalla, Vauthey (bb0150) 2008; 15 Welch, Spithoff, Rumble, Maroun (bb0060) 2010; 21 Zalinski, Bigourdan, Vauthey (bb0135) 2010; 147 Maru, Kopetz, Boonsirikamchai, Agarwal, Chun, Wang (bb0185) 2010; 34 Hemming, Reed, Howard, Fujita, Hochwald, Caridi (bb0065) 2003; 237 Wicherts, de Haas, Andreani, Sotirov, Salloum, Castaing (bb0080) 2010; 97 Kopetz, Chang, Overman, Eng, Sargent, Larson (bb0025) 2009; 27 Vauthey, Zorzi (bb0165) 2009; 16 Abdalla, Barnett, Doherty, Curley, Vauthey (bb0070) 2002; 137 Kokudo, Tada, Seki, Ohta, Azekura, Ueno (bb0100) 2001; 34 Abulkhir, Limongelli, Healey, Curley, Vauthey (bb0075) 2008; 247 Barbaro, Di Stasi, Nuzzo, Vellone, Giuliante, Marano (bb0110) 2003; 44 Tanaka, Kumamoto, Matsuyama, Takeda, Nagano, Endo (bb0095) 2010; 14 Covey, Brown, Jarnagin, Brody, Schwartz, Tuorto (bb0090) 2008; 247 Jemal, Siegel, Xu, Ward (bb0010) 2010; 60 Loupakis, Bria, Vaccaro, Cuppone, Milella, Carlini (bb0055) 2010; 29 Maggiori L, Bretagnol F, Sibert A, Paradis V, Vilgrain V, Panis Y. (2010) Selective portal vein ligation and embolization induce different tumoral responses in the rat liver. Surgery 149:496-503. Vauthey JN, Zorzi D. (2009) In search of the black sheep: is it bevacizumab or extended chemotherapy? Ann Surg Oncol 16:1463-1464. Abdalla EK, Barnett CC, Doherty D, Curley SA, Vauthey JN. (2002) Extended hepatectomy in patients with hepatobiliary malignancies with and without preoperative portal vein embolization. Arch Surg 137:675-680; discussion 680-681. Zorzi D, Chun YS, Madoff DC, Abdalla EK, Vauthey JN. (2008) Chemotherapy with bevacizumab does not affect liver regeneration after portal vein embolization in the treatment of colorectal liver metastases. Ann Surg Oncol 15:2765-2772. Sturesson C, Keussen I, Tranberg KG. (2010) Prolonged chemotherapy impairs liver regeneration after portal vein occlusion - an audit of 26 patients. Eur J Surg Oncol 36:358-364. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W et al. (2004) Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350:2335-2342. Gruenberger B, Tamandl D, Schueller J, Scheithauer W, Zielinski C, Herbst F et al. (2008) Bevacizumab, capecitabine, and oxaliplatin as neoadjuvant therapy for patients with potentially curable metastatic colorectal cancer. J Clin Oncol 26:1830-1835. Barbaro B, Di Stasi C, Nuzzo G, Vellone M, Giuliante F, Marano P. (2003) Preoperative right portal vein embolization in patients with metastatic liver disease. Metastatic liver volumes after RPVE. Acta Radiol 44:98-102. Abulkhir A, Limongelli P, Healey AJ, Curley SA, Vauthey JN. (2008) Preoperative portal vein embolization for major liver resection: a meta-analysis. Ann Surg 247:49-57. Donadon M, Ribero D, Morris-Stiff G, Abdalla EK, Vauthey JN. (2007) New paradigm in the management of liver-only metastases from colorectal cancer. Gastrointest Cancer Res 1:20-27. Zalinski S, Bigourdan JM, Vauthey JN. (2010) Does bevacizumab have a protective effect on hepatotoxicity induced by chemotherapy? J Chir (Paris) 147 (Suppl 1):18-24. Kopetz S, Chang GJ, Overman MJ, Eng C, Sargent DJ, Larson DW et al. (2009) Improved survival in metastatic colorectal cancer is associated with adoption of hepatic resection and improved chemotherapy. J Clin Oncol 27:3677-3683. Aussilhou B, Dokmak S, Faivre S, Paradis V, Vilgrain V, Belghiti J. (2009) Preoperative liver hypertrophy induced by portal flow occlusion before major hepatic resection for colorectal metastases can be impaired by bevacizumab. Ann Surg Oncol 16:1553-1559. Kokudo N, Tada K, Seki M, Ohta H, Azekura K, Ueno M et al. (2001) Proliferative activity of intrahepatic colorectal metastases after preoperative hemihepatic portal vein embolization. Hepatology 34:267-272. Welch S, Spithoff K, Rumble RB, Maroun J, Gastrointestinal Cancer Disease Site Group. (2010) Bevacizumab combined with chemotherapy for patients with advanced colorectal cancer: a systematic review. Ann Oncol 21:1152-1162. Siegel R, Naishadham D, Jemal A. (2012) Cancer statistics, 2012. CA Cancer J Clin 62:10-29. Sanoff HK, Sargent DJ, Campbell ME, Morton RF, Fuchs CS, Ramanathan RK et al. (2008) Five-year data and prognostic factor analysis of oxaliplatin and irinotecan combinations for advanced colorectal cancer: N9741. J Clin Oncol 26:5721-5727. Wicherts DA, de Haas RJ, Andreani P, Sotirov D, Salloum C, Castaing D et al. (2010) Impact of portal vein embolization on longterm survival of patients with primarily unresectable colorectal liver metastases. Br J Surg 97:240-250. van Gulik TM, van den Esschert JW, de Graaf W, van Lienden KP, Busch OR, Heger M et al. (2008) Controversies in the use of portal vein embolization. Dig Surg 25:436-444. Jemal A, Siegel R, Xu J, Ward E. (2010) Cancer statistics 2010. CA Cancer J Clin 60:277-300. Elias D, De Baere T, Roche A, Ducreux M, Leclere J, Lasser P. (1999) During liver regeneration following right portal embolization the growth rate of liver metastases is more rapid than that of the liver parenchyma. Br J Surg 86:784-788. Heinrich S, Jochum W, Graf R, Clavien PA. (2006) Portal vein ligation and partial hepatectomy differentially influence growth of intrahepatic metastasis and regeneration in mice. J Hepatol 45:35-42. Loupakis F, Bria E, Vaccaro V, Cuppone F, Milella M, Carlini P et al. (2010) Magnitude of benefit of the addition of bevacizumab to first-line chemotherapy for metastatic colorectal cancer: meta-analysis of randomized trials. J Exp Clin Cancer Res 29:58-66. Hemming AW, Reed AI, Howard RJ, Fujita S, Hochwald SN, Caridi JG et al. (2003) Preoperative portal vein embolization for extended hepatectomy. Ann Surg 237:686-691. Hochster HS, Hart LL, Ramanathan RK, Childs BH, Hainsworth JD, Cohn AL et al. (2008) Safety and efficacy of oxaliplatin and fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer: results of the TREE Study. J Clin Oncol 26:3523-3529. Covey AM, Brown KT, Jarnagin WR, Brody LA, Schwartz L, Tuorto S et al. (2008) Combined portal vein embolization and neoadjuvant chemotherapy as a treatment strategy for resectable hepatic colorectal metastases. Ann Surg 247:451-455. Maru DM, Kopetz S, Boonsirikamchai P, Agarwal A, Chun YS, Wang H et al. (2010) Tumour thickness at the tumour-normal interface: a novel pathologic indicator of chemotherapy response in hepatic colorectal metastases. Am J Surg Pathol 34:1287-1294. Engstrom PF, National Comprehensive Cancer Network. (2008) Systemic therapy for advanced or metastatic colorectal cancer: National Comprehensive Cancer Network guidelines for combining anti-vascular endothelial growth factor and anti-epidermal growth factor receptor monoclonal antibodies with chemotherapy. Pharmacotherapy 28 (11 Pt 2):18-22. American Joint Committee on Cancer. (2010) Cancer Staging Manual, 7th edn. Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A, eds. New York, NY: Springer, p. 143. Nafidi O, Désy D, Létourneau R, Côté J, Plasse M, Vandenbroucke F et al. (2009) Hypertrophy of the non-embolized liver after chemotherapy. HPB 11:103-107. Ribero D, Wang H, Donadon M, Zorzi D, Thomas MB, Eng C et al. (2007) Bevacizumab improves pathologic response and protects against hepatic injury in patients treated with oxaliplatin-based chemotherapy for colorectal liver metastases. Cancer 110:2761-2767. Ribero D, Abdalla EK, Madoff DC, Donadon M, Loyer EM, Vauthey JN. (2007) Portal vein embolization before major hepatectomy and its effect on regeneration, resectability and outcome. Br J Surg 94:1386-1394. Chaudhury P, Hassanain M, Bouganim N, Salman A, Kavan P, Metrakos P. (2010) Perioperative chemotherapy with bevacizumab and liver resection for colorectal cancer liver metastasis. HPB 12:37-42. Rubbia-Brandt L, Giostra E, Brezault C, Roth AD, Andres A, Audard V et al. (2007) Importance of histological tumour response assessment in predicting the outcome in patients with colorectal liver metastases treated with neoadjuvant chemotherapy followed by liver surgery. Ann Oncol 18:299-304. Tanaka K, Kumamoto T, Matsuyama R, Takeda K, Nagano Y, Endo I. (2010) Influence of chemotherapy on liver regeneration induced by portal vein embolization or first hepatectomy of a staged procedure for colorectal liver metastases. J Gastrointest Surg 14:359-368. Shah SA, Haddad R, Al-Sukhni W, Kim RD, Greig PD, Grant DR et al. (2006) Surgical resection of hepatic and pulmonary metastases from colorectal carcinoma. J Am Coll Surg 202:468-475. 2010; 12 2010; 34 2007; 18 2010; 97 2010; 14 2010; 36 2003; 237 2010 2010; 149 2010; 147 2008; 15 2002; 137 1999; 86 2008; 247 2007; 94 2009; 27 2010; 60 2009; 11 2010; 21 2006; 45 2010; 29 2004; 350 2007; 110 2008; 28 2008; 25 2008; 26 2001; 34 2007; 1 2009; 16 2006; 202 2003; 44 2012; 62 Shah (10.1111/j.1477-2574.2012.00476.x_bb0030) 2006; 202 Rubbia-Brandt (10.1111/j.1477-2574.2012.00476.x_bb0180) 2007; 18 Heinrich (10.1111/j.1477-2574.2012.00476.x_bb0120) 2006; 45 van Gulik (10.1111/j.1477-2574.2012.00476.x_bb0130) 2008; 25 Engstrom (10.1111/j.1477-2574.2012.00476.x_bb0040) 2008; 28 Sanoff (10.1111/j.1477-2574.2012.00476.x_bb0035) 2008; 26 Hochster (10.1111/j.1477-2574.2012.00476.x_bb0050) 2008; 26 Abulkhir (10.1111/j.1477-2574.2012.00476.x_bb0075) 2008; 247 Ribero (10.1111/j.1477-2574.2012.00476.x_bb0115) 2007; 94 Siegel (10.1111/j.1477-2574.2012.00476.x_bb0015) 2012; 62 (10.1111/j.1477-2574.2012.00476.x_bb0020) 2010 Donadon (10.1111/j.1477-2574.2012.00476.x_bb0170) 2007; 1 Kokudo (10.1111/j.1477-2574.2012.00476.x_bb0100) 2001; 34 Zorzi (10.1111/j.1477-2574.2012.00476.x_bb0150) 2008; 15 Hurwitz (10.1111/j.1477-2574.2012.00476.x_bb0045) 2004; 350 Welch (10.1111/j.1477-2574.2012.00476.x_bb0060) 2010; 21 Wicherts (10.1111/j.1477-2574.2012.00476.x_bb0080) 2010; 97 Nafidi (10.1111/j.1477-2574.2012.00476.x_bb0085) 2009; 11 Covey (10.1111/j.1477-2574.2012.00476.x_bb0090) 2008; 247 Elias (10.1111/j.1477-2574.2012.00476.x_bb0105) 1999; 86 Zalinski (10.1111/j.1477-2574.2012.00476.x_bb0135) 2010; 147 Jemal (10.1111/j.1477-2574.2012.00476.x_bb0010) 2010; 60 Sturesson (10.1111/j.1477-2574.2012.00476.x_bb0160) 2010; 36 Kopetz (10.1111/j.1477-2574.2012.00476.x_bb0025) 2009; 27 Gruenberger (10.1111/j.1477-2574.2012.00476.x_bb0140) 2008; 26 Hemming (10.1111/j.1477-2574.2012.00476.x_bb0065) 2003; 237 Abdalla (10.1111/j.1477-2574.2012.00476.x_bb0070) 2002; 137 Aussilhou (10.1111/j.1477-2574.2012.00476.x_bb0155) 2009; 16 Ribero (10.1111/j.1477-2574.2012.00476.x_bb0175) 2007; 110 Maru (10.1111/j.1477-2574.2012.00476.x_bb0185) 2010; 34 Chaudhury (10.1111/j.1477-2574.2012.00476.x_bb0145) 2010; 12 Tanaka (10.1111/j.1477-2574.2012.00476.x_bb0095) 2010; 14 Loupakis (10.1111/j.1477-2574.2012.00476.x_bb0055) 2010; 29 Barbaro (10.1111/j.1477-2574.2012.00476.x_bb0110) 2003; 44 Vauthey (10.1111/j.1477-2574.2012.00476.x_bb0165) 2009; 16 Maggiori (10.1111/j.1477-2574.2012.00476.x_bb0125) 2010; 149 17060484 - Ann Oncol. 2007 Feb;18(2):299-304 20100648 - Eur J Surg Oncol. 2010 Apr;36(4):358-64 19888636 - J Gastrointest Surg. 2010 Feb;14(2):359-68 19262699 - Gastrointest Cancer Res. 2007 Jan;1(1):20-7 18980548 - Pharmacotherapy. 2008 Nov;28(11 Pt 2):18S-22S 21167542 - Surgery. 2011 Apr;149(4):496-503 20504361 - J Exp Clin Cancer Res. 2010;29:58 17583900 - Br J Surg. 2007 Nov;94(11):1386-94 15175435 - N Engl J Med. 2004 Jun 3;350(23):2335-42 19470929 - J Clin Oncol. 2009 Aug 1;27(22):3677-83 12631007 - Acta Radiol. 2003 Jan;44(1):98-102 17960603 - Cancer. 2007 Dec 15;110(12):2761-7 20610543 - CA Cancer J Clin. 2010 Sep-Oct;60(5):277-300 18398148 - J Clin Oncol. 2008 Apr 10;26(11):1830-5 18376189 - Ann Surg. 2008 Mar;247(3):451-5 16500252 - J Am Coll Surg. 2006 Mar;202(3):468-75 12724635 - Ann Surg. 2003 May;237(5):686-91; discussion 691-3 20172201 - J Chir (Paris). 2010 Jan;147 Suppl 1:S18-24 19590632 - HPB (Oxford). 2009 Mar;11(2):103-7 11481611 - Hepatology. 2001 Aug;34(2):267-72 19363584 - Ann Surg Oncol. 2009 Jun;16(6):1553-9 19942597 - Ann Oncol. 2010 Jun;21(6):1152-62 20697255 - Am J Surg Pathol. 2010 Sep;34(9):1287-94 10383579 - Br J Surg. 1999 Jun;86(6):784-8 18636296 - Ann Surg Oncol. 2008 Oct;15(10):2765-72 18640933 - J Clin Oncol. 2008 Jul 20;26(21):3523-9 22237781 - CA Cancer J Clin. 2012 Jan-Feb;62(1):10-29 19357926 - Ann Surg Oncol. 2009 Jun;16(6):1463-4 16698111 - J Hepatol. 2006 Jul;45(1):35-42 19001325 - J Clin Oncol. 2008 Dec 10;26(35):5721-7 12049538 - Arch Surg. 2002 Jun;137(6):675-80; discussion 680-1 18156923 - Ann Surg. 2008 Jan;247(1):49-57 20495643 - HPB (Oxford). 2010 Feb;12(1):37-42 19212116 - Dig Surg. 2008;25(6):436-44 20087967 - Br J Surg. 2010 Feb;97(2):240-50 |
| References_xml | – volume: 11 start-page: 103 year: 2009 end-page: 107 ident: bb0085 article-title: Hypertrophy of the non-embolized liver after chemotherapy publication-title: HPB – volume: 34 start-page: 267 year: 2001 end-page: 272 ident: bb0100 article-title: Proliferative activity of intrahepatic colorectal metastases after preoperative hemihepatic portal vein embolization publication-title: Hepatology – volume: 60 start-page: 277 year: 2010 end-page: 300 ident: bb0010 article-title: Cancer statistics 2010 publication-title: CA Cancer J Clin – volume: 14 start-page: 359 year: 2010 end-page: 368 ident: bb0095 article-title: Influence of chemotherapy on liver regeneration induced by portal vein embolization or first hepatectomy of a staged procedure for colorectal liver metastases publication-title: J Gastrointest Surg – volume: 21 start-page: 1152 year: 2010 end-page: 1162 ident: bb0060 article-title: Bevacizumab combined with chemotherapy for patients with advanced colorectal cancer: a systematic review publication-title: Ann Oncol – volume: 12 start-page: 37 year: 2010 end-page: 42 ident: bb0145 article-title: Perioperative chemotherapy with bevacizumab and liver resection for colorectal cancer liver metastasis publication-title: HPB – volume: 34 start-page: 1287 year: 2010 end-page: 1294 ident: bb0185 article-title: Tumour thickness at the tumour–normal interface: a novel pathologic indicator of chemotherapy response in hepatic colorectal metastases publication-title: Am J Surg Pathol – volume: 18 start-page: 299 year: 2007 end-page: 304 ident: bb0180 article-title: Importance of histological tumour response assessment in predicting the outcome in patients with colorectal liver metastases treated with neoadjuvant chemotherapy followed by liver surgery publication-title: Ann Oncol – volume: 28 start-page: 18 year: 2008 end-page: 22 ident: bb0040 article-title: Systemic therapy for advanced or metastatic colorectal cancer: National Comprehensive Cancer Network guidelines for combining anti-vascular endothelial growth factor and anti-epidermal growth factor receptor monoclonal antibodies with chemotherapy publication-title: Pharmacotherapy – volume: 25 start-page: 436 year: 2008 end-page: 444 ident: bb0130 article-title: Controversies in the use of portal vein embolization publication-title: Dig Surg – volume: 44 start-page: 98 year: 2003 end-page: 102 ident: bb0110 article-title: Preoperative right portal vein embolization in patients with metastatic liver disease. Metastatic liver volumes after RPVE publication-title: Acta Radiol – volume: 247 start-page: 49 year: 2008 end-page: 57 ident: bb0075 article-title: Preoperative portal vein embolization for major liver resection: a meta-analysis publication-title: Ann Surg – volume: 94 start-page: 1386 year: 2007 end-page: 1394 ident: bb0115 article-title: Portal vein embolization before major hepatectomy and its effect on regeneration, resectability and outcome publication-title: Br J Surg – start-page: 143 year: 2010 ident: bb0020 article-title: Cancer Staging Manual – volume: 26 start-page: 1830 year: 2008 end-page: 1835 ident: bb0140 article-title: Bevacizumab, capecitabine, and oxaliplatin as neoadjuvant therapy for patients with potentially curable metastatic colorectal cancer publication-title: J Clin Oncol – volume: 247 start-page: 451 year: 2008 end-page: 455 ident: bb0090 article-title: Combined portal vein embolization and neoadjuvant chemotherapy as a treatment strategy for resectable hepatic colorectal metastases publication-title: Ann Surg – volume: 27 start-page: 3677 year: 2009 end-page: 3683 ident: bb0025 article-title: Improved survival in metastatic colorectal cancer is associated with adoption of hepatic resection and improved chemotherapy publication-title: J Clin Oncol – volume: 110 start-page: 2761 year: 2007 end-page: 2767 ident: bb0175 article-title: Bevacizumab improves pathologic response and protects against hepatic injury in patients treated with oxaliplatin-based chemotherapy for colorectal liver metastases publication-title: Cancer – volume: 16 start-page: 1553 year: 2009 end-page: 1559 ident: bb0155 article-title: Preoperative liver hypertrophy induced by portal flow occlusion before major hepatic resection for colorectal metastases can be impaired by bevacizumab publication-title: Ann Surg Oncol – volume: 26 start-page: 3523 year: 2008 end-page: 3529 ident: bb0050 article-title: Safety and efficacy of oxaliplatin and fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer: results of the TREE Study publication-title: J Clin Oncol – volume: 86 start-page: 784 year: 1999 end-page: 788 ident: bb0105 article-title: During liver regeneration following right portal embolization the growth rate of liver metastases is more rapid than that of the liver parenchyma publication-title: Br J Surg – volume: 45 start-page: 35 year: 2006 end-page: 42 ident: bb0120 article-title: Portal vein ligation and partial hepatectomy differentially influence growth of intrahepatic metastasis and regeneration in mice publication-title: J Hepatol – volume: 350 start-page: 2335 year: 2004 end-page: 2342 ident: bb0045 article-title: Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer publication-title: N Engl J Med – volume: 97 start-page: 240 year: 2010 end-page: 250 ident: bb0080 article-title: Impact of portal vein embolization on longterm survival of patients with primarily unresectable colorectal liver metastases publication-title: Br J Surg – volume: 147 start-page: 18 year: 2010 end-page: 24 ident: bb0135 article-title: Does bevacizumab have a protective effect on hepatotoxicity induced by chemotherapy? publication-title: J Chir (Paris) – volume: 149 start-page: 496 year: 2010 end-page: 503 ident: bb0125 article-title: Selective portal vein ligation and embolization induce different tumoral responses in the rat liver publication-title: Surgery – volume: 16 start-page: 1463 year: 2009 end-page: 1464 ident: bb0165 article-title: In search of the black sheep: is it bevacizumab or extended chemotherapy? publication-title: Ann Surg Oncol – volume: 137 start-page: 675 year: 2002 end-page: 680 ident: bb0070 article-title: Extended hepatectomy in patients with hepatobiliary malignancies with and without preoperative portal vein embolization publication-title: Arch Surg – volume: 202 start-page: 468 year: 2006 end-page: 475 ident: bb0030 article-title: Surgical resection of hepatic and pulmonary metastases from colorectal carcinoma publication-title: J Am Coll Surg – volume: 29 start-page: 58 year: 2010 end-page: 66 ident: bb0055 article-title: Magnitude of benefit of the addition of bevacizumab to first-line chemotherapy for metastatic colorectal cancer: meta-analysis of randomized trials publication-title: J Exp Clin Cancer Res – volume: 1 start-page: 20 year: 2007 end-page: 27 ident: bb0170 article-title: New paradigm in the management of liver-only metastases from colorectal cancer publication-title: Gastrointest Cancer Res – volume: 26 start-page: 5721 year: 2008 end-page: 5727 ident: bb0035 article-title: Five-year data and prognostic factor analysis of oxaliplatin and irinotecan combinations for advanced colorectal cancer: N9741 publication-title: J Clin Oncol – volume: 237 start-page: 686 year: 2003 end-page: 691 ident: bb0065 article-title: Preoperative portal vein embolization for extended hepatectomy publication-title: Ann Surg – volume: 15 start-page: 2765 year: 2008 end-page: 2772 ident: bb0150 article-title: Chemotherapy with bevacizumab does not affect liver regeneration after portal vein embolization in the treatment of colorectal liver metastases publication-title: Ann Surg Oncol – volume: 62 start-page: 10 year: 2012 end-page: 29 ident: bb0015 article-title: Cancer statistics, 2012 publication-title: CA Cancer J Clin – volume: 36 start-page: 358 year: 2010 end-page: 364 ident: bb0160 article-title: Prolonged chemotherapy impairs liver regeneration after portal vein occlusion – an audit of 26 patients publication-title: Eur J Surg Oncol – reference: Wicherts DA, de Haas RJ, Andreani P, Sotirov D, Salloum C, Castaing D et al. (2010) Impact of portal vein embolization on longterm survival of patients with primarily unresectable colorectal liver metastases. Br J Surg 97:240-250. – reference: Ribero D, Wang H, Donadon M, Zorzi D, Thomas MB, Eng C et al. (2007) Bevacizumab improves pathologic response and protects against hepatic injury in patients treated with oxaliplatin-based chemotherapy for colorectal liver metastases. Cancer 110:2761-2767. – reference: Kopetz S, Chang GJ, Overman MJ, Eng C, Sargent DJ, Larson DW et al. (2009) Improved survival in metastatic colorectal cancer is associated with adoption of hepatic resection and improved chemotherapy. J Clin Oncol 27:3677-3683. – reference: Kokudo N, Tada K, Seki M, Ohta H, Azekura K, Ueno M et al. (2001) Proliferative activity of intrahepatic colorectal metastases after preoperative hemihepatic portal vein embolization. Hepatology 34:267-272. – reference: Abdalla EK, Barnett CC, Doherty D, Curley SA, Vauthey JN. (2002) Extended hepatectomy in patients with hepatobiliary malignancies with and without preoperative portal vein embolization. Arch Surg 137:675-680; discussion 680-681. – reference: American Joint Committee on Cancer. (2010) Cancer Staging Manual, 7th edn. Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A, eds. New York, NY: Springer, p. 143. – reference: van Gulik TM, van den Esschert JW, de Graaf W, van Lienden KP, Busch OR, Heger M et al. (2008) Controversies in the use of portal vein embolization. Dig Surg 25:436-444. – reference: Chaudhury P, Hassanain M, Bouganim N, Salman A, Kavan P, Metrakos P. (2010) Perioperative chemotherapy with bevacizumab and liver resection for colorectal cancer liver metastasis. HPB 12:37-42. – reference: Ribero D, Abdalla EK, Madoff DC, Donadon M, Loyer EM, Vauthey JN. (2007) Portal vein embolization before major hepatectomy and its effect on regeneration, resectability and outcome. Br J Surg 94:1386-1394. – reference: Zalinski S, Bigourdan JM, Vauthey JN. (2010) Does bevacizumab have a protective effect on hepatotoxicity induced by chemotherapy? J Chir (Paris) 147 (Suppl 1):18-24. – reference: Siegel R, Naishadham D, Jemal A. (2012) Cancer statistics, 2012. CA Cancer J Clin 62:10-29. – reference: Abulkhir A, Limongelli P, Healey AJ, Curley SA, Vauthey JN. (2008) Preoperative portal vein embolization for major liver resection: a meta-analysis. Ann Surg 247:49-57. – reference: Vauthey JN, Zorzi D. (2009) In search of the black sheep: is it bevacizumab or extended chemotherapy? Ann Surg Oncol 16:1463-1464. – reference: Nafidi O, Désy D, Létourneau R, Côté J, Plasse M, Vandenbroucke F et al. (2009) Hypertrophy of the non-embolized liver after chemotherapy. HPB 11:103-107. – reference: Hemming AW, Reed AI, Howard RJ, Fujita S, Hochwald SN, Caridi JG et al. (2003) Preoperative portal vein embolization for extended hepatectomy. Ann Surg 237:686-691. – reference: Welch S, Spithoff K, Rumble RB, Maroun J, Gastrointestinal Cancer Disease Site Group. (2010) Bevacizumab combined with chemotherapy for patients with advanced colorectal cancer: a systematic review. Ann Oncol 21:1152-1162. – reference: Engstrom PF, National Comprehensive Cancer Network. (2008) Systemic therapy for advanced or metastatic colorectal cancer: National Comprehensive Cancer Network guidelines for combining anti-vascular endothelial growth factor and anti-epidermal growth factor receptor monoclonal antibodies with chemotherapy. Pharmacotherapy 28 (11 Pt 2):18-22. – reference: Rubbia-Brandt L, Giostra E, Brezault C, Roth AD, Andres A, Audard V et al. (2007) Importance of histological tumour response assessment in predicting the outcome in patients with colorectal liver metastases treated with neoadjuvant chemotherapy followed by liver surgery. Ann Oncol 18:299-304. – reference: Covey AM, Brown KT, Jarnagin WR, Brody LA, Schwartz L, Tuorto S et al. (2008) Combined portal vein embolization and neoadjuvant chemotherapy as a treatment strategy for resectable hepatic colorectal metastases. Ann Surg 247:451-455. – reference: Donadon M, Ribero D, Morris-Stiff G, Abdalla EK, Vauthey JN. (2007) New paradigm in the management of liver-only metastases from colorectal cancer. Gastrointest Cancer Res 1:20-27. – reference: Shah SA, Haddad R, Al-Sukhni W, Kim RD, Greig PD, Grant DR et al. (2006) Surgical resection of hepatic and pulmonary metastases from colorectal carcinoma. J Am Coll Surg 202:468-475. – reference: Maggiori L, Bretagnol F, Sibert A, Paradis V, Vilgrain V, Panis Y. (2010) Selective portal vein ligation and embolization induce different tumoral responses in the rat liver. Surgery 149:496-503. – reference: Heinrich S, Jochum W, Graf R, Clavien PA. (2006) Portal vein ligation and partial hepatectomy differentially influence growth of intrahepatic metastasis and regeneration in mice. J Hepatol 45:35-42. – reference: Maru DM, Kopetz S, Boonsirikamchai P, Agarwal A, Chun YS, Wang H et al. (2010) Tumour thickness at the tumour-normal interface: a novel pathologic indicator of chemotherapy response in hepatic colorectal metastases. Am J Surg Pathol 34:1287-1294. – reference: Hochster HS, Hart LL, Ramanathan RK, Childs BH, Hainsworth JD, Cohn AL et al. (2008) Safety and efficacy of oxaliplatin and fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer: results of the TREE Study. J Clin Oncol 26:3523-3529. – reference: Elias D, De Baere T, Roche A, Ducreux M, Leclere J, Lasser P. (1999) During liver regeneration following right portal embolization the growth rate of liver metastases is more rapid than that of the liver parenchyma. Br J Surg 86:784-788. – reference: Gruenberger B, Tamandl D, Schueller J, Scheithauer W, Zielinski C, Herbst F et al. (2008) Bevacizumab, capecitabine, and oxaliplatin as neoadjuvant therapy for patients with potentially curable metastatic colorectal cancer. J Clin Oncol 26:1830-1835. – reference: Barbaro B, Di Stasi C, Nuzzo G, Vellone M, Giuliante F, Marano P. (2003) Preoperative right portal vein embolization in patients with metastatic liver disease. Metastatic liver volumes after RPVE. Acta Radiol 44:98-102. – reference: Jemal A, Siegel R, Xu J, Ward E. (2010) Cancer statistics 2010. CA Cancer J Clin 60:277-300. – reference: Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W et al. (2004) Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350:2335-2342. – reference: Sanoff HK, Sargent DJ, Campbell ME, Morton RF, Fuchs CS, Ramanathan RK et al. (2008) Five-year data and prognostic factor analysis of oxaliplatin and irinotecan combinations for advanced colorectal cancer: N9741. J Clin Oncol 26:5721-5727. – reference: Aussilhou B, Dokmak S, Faivre S, Paradis V, Vilgrain V, Belghiti J. (2009) Preoperative liver hypertrophy induced by portal flow occlusion before major hepatic resection for colorectal metastases can be impaired by bevacizumab. Ann Surg Oncol 16:1553-1559. – reference: Loupakis F, Bria E, Vaccaro V, Cuppone F, Milella M, Carlini P et al. (2010) Magnitude of benefit of the addition of bevacizumab to first-line chemotherapy for metastatic colorectal cancer: meta-analysis of randomized trials. J Exp Clin Cancer Res 29:58-66. – reference: Sturesson C, Keussen I, Tranberg KG. (2010) Prolonged chemotherapy impairs liver regeneration after portal vein occlusion - an audit of 26 patients. Eur J Surg Oncol 36:358-364. – reference: Tanaka K, Kumamoto T, Matsuyama R, Takeda K, Nagano Y, Endo I. (2010) Influence of chemotherapy on liver regeneration induced by portal vein embolization or first hepatectomy of a staged procedure for colorectal liver metastases. J Gastrointest Surg 14:359-368. – reference: Zorzi D, Chun YS, Madoff DC, Abdalla EK, Vauthey JN. (2008) Chemotherapy with bevacizumab does not affect liver regeneration after portal vein embolization in the treatment of colorectal liver metastases. Ann Surg Oncol 15:2765-2772. – volume: 21 start-page: 1152 year: 2010 end-page: 1162 article-title: Bevacizumab combined with chemotherapy for patients with advanced colorectal cancer: a systematic review publication-title: Ann Oncol – volume: 16 start-page: 1463 year: 2009 end-page: 1464 article-title: In search of the black sheep: is it bevacizumab or extended chemotherapy? publication-title: Ann Surg Oncol – volume: 27 start-page: 3677 year: 2009 end-page: 3683 article-title: Improved survival in metastatic colorectal cancer is associated with adoption of hepatic resection and improved chemotherapy publication-title: J Clin Oncol – volume: 26 start-page: 3523 year: 2008 end-page: 3529 article-title: Safety and efficacy of oxaliplatin and fluoropyrimidine regimens with or without bevacizumab as first‐line treatment of metastatic colorectal cancer: results of the TREE Study publication-title: J Clin Oncol – volume: 97 start-page: 240 year: 2010 end-page: 250 article-title: Impact of portal vein embolization on longterm survival of patients with primarily unresectable colorectal liver metastases publication-title: Br J Surg – volume: 247 start-page: 49 year: 2008 end-page: 57 article-title: Preoperative portal vein embolization for major liver resection: a meta‐analysis publication-title: Ann Surg – volume: 110 start-page: 2761 year: 2007 end-page: 2767 article-title: Bevacizumab improves pathologic response and protects against hepatic injury in patients treated with oxaliplatin‐based chemotherapy for colorectal liver metastases publication-title: Cancer – volume: 137 start-page: 675 year: 2002 end-page: 680 article-title: Extended hepatectomy in patients with hepatobiliary malignancies with and without preoperative portal vein embolization publication-title: Arch Surg – volume: 12 start-page: 37 year: 2010 end-page: 42 article-title: Perioperative chemotherapy with bevacizumab and liver resection for colorectal cancer liver metastasis publication-title: HPB – volume: 25 start-page: 436 year: 2008 end-page: 444 article-title: Controversies in the use of portal vein embolization publication-title: Dig Surg – volume: 237 start-page: 686 year: 2003 end-page: 691 article-title: Preoperative portal vein embolization for extended hepatectomy publication-title: Ann Surg – volume: 60 start-page: 277 year: 2010 end-page: 300 article-title: Cancer statistics 2010 publication-title: CA Cancer J Clin – volume: 45 start-page: 35 year: 2006 end-page: 42 article-title: Portal vein ligation and partial hepatectomy differentially influence growth of intrahepatic metastasis and regeneration in mice publication-title: J Hepatol – volume: 28 start-page: 18 issue: 11 year: 2008 end-page: 22 article-title: Systemic therapy for advanced or metastatic colorectal cancer: National Comprehensive Cancer Network guidelines for combining anti‐vascular endothelial growth factor and anti‐epidermal growth factor receptor monoclonal antibodies with chemotherapy publication-title: Pharmacotherapy – volume: 14 start-page: 359 year: 2010 end-page: 368 article-title: Influence of chemotherapy on liver regeneration induced by portal vein embolization or first hepatectomy of a staged procedure for colorectal liver metastases publication-title: J Gastrointest Surg – volume: 11 start-page: 103 year: 2009 end-page: 107 article-title: Hypertrophy of the non‐embolized liver after chemotherapy publication-title: HPB – volume: 86 start-page: 784 year: 1999 end-page: 788 article-title: During liver regeneration following right portal embolization the growth rate of liver metastases is more rapid than that of the liver parenchyma publication-title: Br J Surg – volume: 147 start-page: 18 issue: 1 year: 2010 end-page: 24 article-title: Does bevacizumab have a protective effect on hepatotoxicity induced by chemotherapy? publication-title: J Chir (Paris) – volume: 34 start-page: 1287 year: 2010 end-page: 1294 article-title: Tumour thickness at the tumour–normal interface: a novel pathologic indicator of chemotherapy response in hepatic colorectal metastases publication-title: Am J Surg Pathol – volume: 29 start-page: 58 year: 2010 end-page: 66 article-title: Magnitude of benefit of the addition of bevacizumab to first‐line chemotherapy for metastatic colorectal cancer: meta‐analysis of randomized trials publication-title: J Exp Clin Cancer Res – volume: 1 start-page: 20 year: 2007 end-page: 27 article-title: New paradigm in the management of liver‐only metastases from colorectal cancer publication-title: Gastrointest Cancer Res – volume: 26 start-page: 5721 year: 2008 end-page: 5727 article-title: Five‐year data and prognostic factor analysis of oxaliplatin and irinotecan combinations for advanced colorectal cancer: N9741 publication-title: J Clin Oncol – volume: 94 start-page: 1386 year: 2007 end-page: 1394 article-title: Portal vein embolization before major hepatectomy and its effect on regeneration, resectability and outcome publication-title: Br J Surg – start-page: 143 year: 2010 – volume: 15 start-page: 2765 year: 2008 end-page: 2772 article-title: Chemotherapy with bevacizumab does not affect liver regeneration after portal vein embolization in the treatment of colorectal liver metastases publication-title: Ann Surg Oncol – volume: 36 start-page: 358 year: 2010 end-page: 364 article-title: Prolonged chemotherapy impairs liver regeneration after portal vein occlusion – an audit of 26 patients publication-title: Eur J Surg Oncol – volume: 350 start-page: 2335 year: 2004 end-page: 2342 article-title: Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer publication-title: N Engl J Med – volume: 44 start-page: 98 year: 2003 end-page: 102 article-title: Preoperative right portal vein embolization in patients with metastatic liver disease. Metastatic liver volumes after RPVE publication-title: Acta Radiol – volume: 62 start-page: 10 year: 2012 end-page: 29 article-title: Cancer statistics, 2012 publication-title: CA Cancer J Clin – volume: 247 start-page: 451 year: 2008 end-page: 455 article-title: Combined portal vein embolization and neoadjuvant chemotherapy as a treatment strategy for resectable hepatic colorectal metastases publication-title: Ann Surg – volume: 34 start-page: 267 year: 2001 end-page: 272 article-title: Proliferative activity of intrahepatic colorectal metastases after preoperative hemihepatic portal vein embolization publication-title: Hepatology – volume: 202 start-page: 468 year: 2006 end-page: 475 article-title: Surgical resection of hepatic and pulmonary metastases from colorectal carcinoma publication-title: J Am Coll Surg – volume: 26 start-page: 1830 year: 2008 end-page: 1835 article-title: Bevacizumab, capecitabine, and oxaliplatin as neoadjuvant therapy for patients with potentially curable metastatic colorectal cancer publication-title: J Clin Oncol – volume: 16 start-page: 1553 year: 2009 end-page: 1559 article-title: Preoperative liver hypertrophy induced by portal flow occlusion before major hepatic resection for colorectal metastases can be impaired by bevacizumab publication-title: Ann Surg Oncol – volume: 149 start-page: 496 year: 2010 end-page: 503 article-title: Selective portal vein ligation and embolization induce different tumoral responses in the rat liver publication-title: Surgery – volume: 18 start-page: 299 year: 2007 end-page: 304 article-title: Importance of histological tumour response assessment in predicting the outcome in patients with colorectal liver metastases treated with neoadjuvant chemotherapy followed by liver surgery publication-title: Ann Oncol – volume: 202 start-page: 468 year: 2006 ident: 10.1111/j.1477-2574.2012.00476.x_bb0030 article-title: Surgical resection of hepatic and pulmonary metastases from colorectal carcinoma publication-title: J Am Coll Surg doi: 10.1016/j.jamcollsurg.2005.11.008 – volume: 26 start-page: 5721 year: 2008 ident: 10.1111/j.1477-2574.2012.00476.x_bb0035 article-title: Five-year data and prognostic factor analysis of oxaliplatin and irinotecan combinations for advanced colorectal cancer: N9741 publication-title: J Clin Oncol doi: 10.1200/JCO.2008.17.7147 – volume: 16 start-page: 1553 year: 2009 ident: 10.1111/j.1477-2574.2012.00476.x_bb0155 article-title: Preoperative liver hypertrophy induced by portal flow occlusion before major hepatic resection for colorectal metastases can be impaired by bevacizumab publication-title: Ann Surg Oncol doi: 10.1245/s10434-009-0447-z – volume: 149 start-page: 496 year: 2010 ident: 10.1111/j.1477-2574.2012.00476.x_bb0125 article-title: Selective portal vein ligation and embolization induce different tumoral responses in the rat liver publication-title: Surgery doi: 10.1016/j.surg.2010.10.012 – volume: 15 start-page: 2765 year: 2008 ident: 10.1111/j.1477-2574.2012.00476.x_bb0150 article-title: Chemotherapy with bevacizumab does not affect liver regeneration after portal vein embolization in the treatment of colorectal liver metastases publication-title: Ann Surg Oncol doi: 10.1245/s10434-008-0035-7 – volume: 110 start-page: 2761 year: 2007 ident: 10.1111/j.1477-2574.2012.00476.x_bb0175 article-title: Bevacizumab improves pathologic response and protects against hepatic injury in patients treated with oxaliplatin-based chemotherapy for colorectal liver metastases publication-title: Cancer doi: 10.1002/cncr.23099 – volume: 29 start-page: 58 year: 2010 ident: 10.1111/j.1477-2574.2012.00476.x_bb0055 article-title: Magnitude of benefit of the addition of bevacizumab to first-line chemotherapy for metastatic colorectal cancer: meta-analysis of randomized trials publication-title: J Exp Clin Cancer Res doi: 10.1186/1756-9966-29-58 – volume: 62 start-page: 10 year: 2012 ident: 10.1111/j.1477-2574.2012.00476.x_bb0015 article-title: Cancer statistics, 2012 publication-title: CA Cancer J Clin doi: 10.3322/caac.20138 – volume: 60 start-page: 277 year: 2010 ident: 10.1111/j.1477-2574.2012.00476.x_bb0010 article-title: Cancer statistics 2010 publication-title: CA Cancer J Clin doi: 10.3322/caac.20073 – volume: 34 start-page: 1287 year: 2010 ident: 10.1111/j.1477-2574.2012.00476.x_bb0185 article-title: Tumour thickness at the tumour–normal interface: a novel pathologic indicator of chemotherapy response in hepatic colorectal metastases publication-title: Am J Surg Pathol doi: 10.1097/PAS.0b013e3181eb2f7b – volume: 14 start-page: 359 year: 2010 ident: 10.1111/j.1477-2574.2012.00476.x_bb0095 article-title: Influence of chemotherapy on liver regeneration induced by portal vein embolization or first hepatectomy of a staged procedure for colorectal liver metastases publication-title: J Gastrointest Surg doi: 10.1007/s11605-009-1073-6 – volume: 45 start-page: 35 year: 2006 ident: 10.1111/j.1477-2574.2012.00476.x_bb0120 article-title: Portal vein ligation and partial hepatectomy differentially influence growth of intrahepatic metastasis and regeneration in mice publication-title: J Hepatol doi: 10.1016/j.jhep.2006.02.020 – volume: 28 start-page: 18 issue: 11 year: 2008 ident: 10.1111/j.1477-2574.2012.00476.x_bb0040 article-title: Systemic therapy for advanced or metastatic colorectal cancer: National Comprehensive Cancer Network guidelines for combining anti-vascular endothelial growth factor and anti-epidermal growth factor receptor monoclonal antibodies with chemotherapy publication-title: Pharmacotherapy doi: 10.1592/phco.28.11-supp.18S – volume: 350 start-page: 2335 year: 2004 ident: 10.1111/j.1477-2574.2012.00476.x_bb0045 article-title: Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer publication-title: N Engl J Med doi: 10.1056/NEJMoa032691 – volume: 97 start-page: 240 year: 2010 ident: 10.1111/j.1477-2574.2012.00476.x_bb0080 article-title: Impact of portal vein embolization on longterm survival of patients with primarily unresectable colorectal liver metastases publication-title: Br J Surg doi: 10.1002/bjs.6756 – volume: 12 start-page: 37 year: 2010 ident: 10.1111/j.1477-2574.2012.00476.x_bb0145 article-title: Perioperative chemotherapy with bevacizumab and liver resection for colorectal cancer liver metastasis publication-title: HPB doi: 10.1111/j.1477-2574.2009.00119.x – start-page: 143 year: 2010 ident: 10.1111/j.1477-2574.2012.00476.x_bb0020 article-title: Cancer Staging Manual – volume: 44 start-page: 98 year: 2003 ident: 10.1111/j.1477-2574.2012.00476.x_bb0110 article-title: Preoperative right portal vein embolization in patients with metastatic liver disease. Metastatic liver volumes after RPVE publication-title: Acta Radiol – volume: 94 start-page: 1386 year: 2007 ident: 10.1111/j.1477-2574.2012.00476.x_bb0115 article-title: Portal vein embolization before major hepatectomy and its effect on regeneration, resectability and outcome publication-title: Br J Surg doi: 10.1002/bjs.5836 – volume: 137 start-page: 675 year: 2002 ident: 10.1111/j.1477-2574.2012.00476.x_bb0070 article-title: Extended hepatectomy in patients with hepatobiliary malignancies with and without preoperative portal vein embolization publication-title: Arch Surg doi: 10.1001/archsurg.137.6.675 – volume: 1 start-page: 20 year: 2007 ident: 10.1111/j.1477-2574.2012.00476.x_bb0170 article-title: New paradigm in the management of liver-only metastases from colorectal cancer publication-title: Gastrointest Cancer Res – volume: 21 start-page: 1152 year: 2010 ident: 10.1111/j.1477-2574.2012.00476.x_bb0060 article-title: Bevacizumab combined with chemotherapy for patients with advanced colorectal cancer: a systematic review publication-title: Ann Oncol doi: 10.1093/annonc/mdp533 – volume: 18 start-page: 299 year: 2007 ident: 10.1111/j.1477-2574.2012.00476.x_bb0180 article-title: Importance of histological tumour response assessment in predicting the outcome in patients with colorectal liver metastases treated with neoadjuvant chemotherapy followed by liver surgery publication-title: Ann Oncol doi: 10.1093/annonc/mdl386 – volume: 25 start-page: 436 year: 2008 ident: 10.1111/j.1477-2574.2012.00476.x_bb0130 article-title: Controversies in the use of portal vein embolization publication-title: Dig Surg doi: 10.1159/000184735 – volume: 147 start-page: 18 issue: 1 year: 2010 ident: 10.1111/j.1477-2574.2012.00476.x_bb0135 article-title: Does bevacizumab have a protective effect on hepatotoxicity induced by chemotherapy? publication-title: J Chir (Paris) – volume: 34 start-page: 267 year: 2001 ident: 10.1111/j.1477-2574.2012.00476.x_bb0100 article-title: Proliferative activity of intrahepatic colorectal metastases after preoperative hemihepatic portal vein embolization publication-title: Hepatology doi: 10.1053/jhep.2001.26513 – volume: 86 start-page: 784 year: 1999 ident: 10.1111/j.1477-2574.2012.00476.x_bb0105 article-title: During liver regeneration following right portal embolization the growth rate of liver metastases is more rapid than that of the liver parenchyma publication-title: Br J Surg doi: 10.1046/j.1365-2168.1999.01154.x – volume: 27 start-page: 3677 year: 2009 ident: 10.1111/j.1477-2574.2012.00476.x_bb0025 article-title: Improved survival in metastatic colorectal cancer is associated with adoption of hepatic resection and improved chemotherapy publication-title: J Clin Oncol doi: 10.1200/JCO.2008.20.5278 – volume: 237 start-page: 686 year: 2003 ident: 10.1111/j.1477-2574.2012.00476.x_bb0065 article-title: Preoperative portal vein embolization for extended hepatectomy publication-title: Ann Surg doi: 10.1097/01.SLA.0000065265.16728.C0 – volume: 26 start-page: 1830 year: 2008 ident: 10.1111/j.1477-2574.2012.00476.x_bb0140 article-title: Bevacizumab, capecitabine, and oxaliplatin as neoadjuvant therapy for patients with potentially curable metastatic colorectal cancer publication-title: J Clin Oncol doi: 10.1200/JCO.2007.13.7679 – volume: 247 start-page: 49 year: 2008 ident: 10.1111/j.1477-2574.2012.00476.x_bb0075 article-title: Preoperative portal vein embolization for major liver resection: a meta-analysis publication-title: Ann Surg doi: 10.1097/SLA.0b013e31815f6e5b – volume: 36 start-page: 358 year: 2010 ident: 10.1111/j.1477-2574.2012.00476.x_bb0160 article-title: Prolonged chemotherapy impairs liver regeneration after portal vein occlusion – an audit of 26 patients publication-title: Eur J Surg Oncol doi: 10.1016/j.ejso.2009.12.001 – volume: 16 start-page: 1463 year: 2009 ident: 10.1111/j.1477-2574.2012.00476.x_bb0165 article-title: In search of the black sheep: is it bevacizumab or extended chemotherapy? publication-title: Ann Surg Oncol doi: 10.1245/s10434-009-0450-4 – volume: 26 start-page: 3523 year: 2008 ident: 10.1111/j.1477-2574.2012.00476.x_bb0050 article-title: Safety and efficacy of oxaliplatin and fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer: results of the TREE Study publication-title: J Clin Oncol doi: 10.1200/JCO.2007.15.4138 – volume: 11 start-page: 103 year: 2009 ident: 10.1111/j.1477-2574.2012.00476.x_bb0085 article-title: Hypertrophy of the non-embolized liver after chemotherapy publication-title: HPB doi: 10.1111/j.1477-2574.2009.00004.x – volume: 247 start-page: 451 year: 2008 ident: 10.1111/j.1477-2574.2012.00476.x_bb0090 article-title: Combined portal vein embolization and neoadjuvant chemotherapy as a treatment strategy for resectable hepatic colorectal metastases publication-title: Ann Surg doi: 10.1097/SLA.0b013e31815ed693 – reference: 12049538 - Arch Surg. 2002 Jun;137(6):675-80; discussion 680-1 – reference: 11481611 - Hepatology. 2001 Aug;34(2):267-72 – reference: 19357926 - Ann Surg Oncol. 2009 Jun;16(6):1463-4 – reference: 19942597 - Ann Oncol. 2010 Jun;21(6):1152-62 – reference: 20172201 - J Chir (Paris). 2010 Jan;147 Suppl 1:S18-24 – reference: 16500252 - J Am Coll Surg. 2006 Mar;202(3):468-75 – reference: 18376189 - Ann Surg. 2008 Mar;247(3):451-5 – reference: 20100648 - Eur J Surg Oncol. 2010 Apr;36(4):358-64 – reference: 18398148 - J Clin Oncol. 2008 Apr 10;26(11):1830-5 – reference: 10383579 - Br J Surg. 1999 Jun;86(6):784-8 – reference: 18636296 - Ann Surg Oncol. 2008 Oct;15(10):2765-72 – reference: 19888636 - J Gastrointest Surg. 2010 Feb;14(2):359-68 – reference: 12631007 - Acta Radiol. 2003 Jan;44(1):98-102 – reference: 18980548 - Pharmacotherapy. 2008 Nov;28(11 Pt 2):18S-22S – reference: 20610543 - CA Cancer J Clin. 2010 Sep-Oct;60(5):277-300 – reference: 20697255 - Am J Surg Pathol. 2010 Sep;34(9):1287-94 – reference: 20504361 - J Exp Clin Cancer Res. 2010;29:58 – reference: 19212116 - Dig Surg. 2008;25(6):436-44 – reference: 12724635 - Ann Surg. 2003 May;237(5):686-91; discussion 691-3 – reference: 19363584 - Ann Surg Oncol. 2009 Jun;16(6):1553-9 – reference: 19590632 - HPB (Oxford). 2009 Mar;11(2):103-7 – reference: 22237781 - CA Cancer J Clin. 2012 Jan-Feb;62(1):10-29 – reference: 17960603 - Cancer. 2007 Dec 15;110(12):2761-7 – reference: 19470929 - J Clin Oncol. 2009 Aug 1;27(22):3677-83 – reference: 17583900 - Br J Surg. 2007 Nov;94(11):1386-94 – reference: 17060484 - Ann Oncol. 2007 Feb;18(2):299-304 – reference: 20087967 - Br J Surg. 2010 Feb;97(2):240-50 – reference: 18156923 - Ann Surg. 2008 Jan;247(1):49-57 – reference: 19262699 - Gastrointest Cancer Res. 2007 Jan;1(1):20-7 – reference: 16698111 - J Hepatol. 2006 Jul;45(1):35-42 – reference: 19001325 - J Clin Oncol. 2008 Dec 10;26(35):5721-7 – reference: 18640933 - J Clin Oncol. 2008 Jul 20;26(21):3523-9 – reference: 21167542 - Surgery. 2011 Apr;149(4):496-503 – reference: 15175435 - N Engl J Med. 2004 Jun 3;350(23):2335-42 – reference: 20495643 - HPB (Oxford). 2010 Feb;12(1):37-42 |
| SSID | ssj0021019 |
| Score | 2.2426524 |
| Snippet | Portal vein embolization (PVE) can facilitate the resection of previously unresectable colorectal cancer (CRC) liver metastases. Bevacizumab is being used... Abstract Objectives Portal vein embolization (PVE) can facilitate the resection of previously unresectable colorectal cancer (CRC) liver metastases.... Objectives: Portal vein embolization (PVE) can facilitate the resection of previously unresectable colorectal cancer (CRC) liver metastases. Bevacizumab is... |
| SourceID | pubmedcentral proquest pubmed crossref wiley istex elsevier |
| SourceType | Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 461 |
| SubjectTerms | Angiogenesis Inhibitors - administration & dosage Antibodies, Monoclonal, Humanized - administration & dosage Bevacizumab Chemotherapy, Adjuvant Chi-Square Distribution colorectal cancer liver metastases Colorectal Neoplasms - pathology degree of hypertrophy Embolization, Therapeutic - adverse effects Female Gastroenterology and Hepatology Hepatectomy Humans Liver Neoplasms - diagnostic imaging Liver Neoplasms - secondary Liver Neoplasms - therapy liver regeneration Liver Regeneration - drug effects Male Neoadjuvant Therapy Original Portal Vein portal vein embolization Quebec Retrospective Studies Risk Assessment Risk Factors Time Factors Tomography, X-Ray Computed Treatment Outcome Tumor Burden - drug effects tumour growth |
| Title | Portal vein embolization stimulates tumour growth in patients with colorectal cancer liver metastases |
| URI | https://www.clinicalkey.com/#!/content/1-s2.0-S1365182X15306134 https://www.clinicalkey.es/playcontent/1-s2.0-S1365182X15306134 https://dx.doi.org/10.1111/j.1477-2574.2012.00476.x https://api.istex.fr/ark:/67375/WNG-NWWT1WKL-K/fulltext.pdf https://onlinelibrary.wiley.com/doi/abs/10.1111%2Fj.1477-2574.2012.00476.x https://www.ncbi.nlm.nih.gov/pubmed/22672548 https://www.proquest.com/docview/1019613416 https://pubmed.ncbi.nlm.nih.gov/PMC3384876 |
| Volume | 14 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1bb9MwFLbKJiFeEHfKTUZCvFRBy9WJeBoIVjFWIW1T-2Y5js0GaTc17VT26znHdi4VHSq8RFEcO5fvi32O8_kcQt6EscyzIBBekTHpRVLnXpYx7e0JHWOyHLZn0gEdjZLhafRlEk96vevu6pJF_k5eb1xX8j-owjHAFVfJ_gOyTaNwAPYBX9gCwrDdCmMrAx1cKYz7Mc0vSreocgDf7RTzcmH8hiU49_PBd3C3F2Z2w0VSrWrVOTjs0OlhmBAkwHxQolIDM0sLMBwrJzF05uvw2wcTn3RVS-JdDpDOfMIxgD9TYmlKr1pClT_Otbb_7AFcUTTni9JNwu7_Eo0GB_NCl2dg2Nuikahcyuh6hsJv1awwwNheNWIYDsKm42m63ahDL9bpQyMbnf0vfbtrDYV5GG41YonVfHYgv5wazMG4ZOACp-1o12gQ66JbZDdgzPziP5g08iDwhP1sXfm18bIYTNo1dJNls4vf62qTB_OnELfrIBkL5-QeuetcE7pveXaf9NTsAbl95MQXD4mydKNIN9qlG23pRi3dqKUbhRNrulGkG23pRi3dqKEbben2iJx-_nTycei5LB2eTMA39aK8kIXUwheJLyVTSgSxTgKdskwyrQSujFZSF1mS6rAQiUgw4n8Ya5b5gYhY-JjszICYTwmNgyjOFeCfagWGskyhEc1kJDAEVZAnfcLqN8ylC2GPmVRK3nVlGeMIE0eYuIGJr_rEb2pe2jAuW9TJahB5vUwZBlYOfNyiLttUV1Wu96i4zys4mx-jzBR8_AlYHmhaR33yvqnpjGBr3G553beGbc1DivlPlG6ymI9HB3w0Hp_448Ov_LBPXtd05DCg4F9CMVMXywo1nxneiA-v-4mlZ9NaTXV4vDXiNidgsPr1ktn5mQlaH4ZpBJZXn8SG4lujwKFng51nN97Lc3Kn7XRekJ3FfKlegqOwyF-ZL_o33P0NwA |
| linkProvider | Geneva Foundation for Medical Education and Research |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Portal+vein+embolization+stimulates+tumour+growth+in+patients+with+colorectal+cancer+liver+metastases&rft.jtitle=HPB+%28Oxford%2C+England%29&rft.au=Simoneau%2C+Eve&rft.au=Aljiffry%2C+Murad&rft.au=Salman%2C+Ayat&rft.au=Abualhassan%2C+Nasser&rft.date=2012-07-01&rft.eissn=1477-2574&rft.volume=14&rft.issue=7&rft.spage=461&rft_id=info:doi/10.1111%2Fj.1477-2574.2012.00476.x&rft_id=info%3Apmid%2F22672548&rft.externalDocID=22672548 |
| thumbnail_m | http://utb.summon.serialssolutions.com/2.0.0/image/custom?url=https%3A%2F%2Fcdn.clinicalkey.com%2Fck-thumbnails%2F1365182X%2FS1365182X12X47002%2Fcov150h.gif |